Taken together, we might be in front of an integrated mechanism in cancer in which the interaction between the insulin/IGF system and metabolic changes might culminate in alterations of the glycosylation of cancer cells that, in turn, fine tune insulin/IGF signaling with major effects on tumour cell development and progression, a biological network that is worth exploring (Figure 2). This evidence concerns the gene IGF1 and cancer.